<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4519">
  <stage>Registered</stage>
  <submitdate>20/03/2014</submitdate>
  <approvaldate>20/03/2014</approvaldate>
  <nctid>NCT02094586</nctid>
  <trial_identification>
    <studytitle>A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Adults</studytitle>
    <scientifictitle>A Phase III Randomized, Double-blind, Placebo-Controlled Three-Lot Consistency Study in Healthy Adult Volunteers to Assess Immunogenicity, and Clinical Acceptability of a Single-dose of the Live Oral Cholera Vaccine Candidate PXVX0200, Vibrio Cholerae O1 Serotype Inaba Vaccine Strain CVD 103-HgR</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PXVX-VC-200-004</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cholera</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - PXVX0200
Other interventions - Placebo

Experimental: PXVX0200 - PXVX0200 Single dose; liquid suspension after reconstitution with buffer; &gt; 2x108 CFU in a liquid suspension

Placebo Comparator: Placebo - Placebo physiological saline


Other interventions: PXVX0200
comparing 3 lots of PXVX0200

Other interventions: Placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The geometric mean antibody titer (GMT) of each lot must be within ± 50% of each other lot with 95% confidence.</outcome>
      <timepoint>Measured 10 days following vaccination</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of vaccinees with at least a 4-fold rise vibriocidal antibody</outcome>
      <timepoint>Measured 10 days after vaccination</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>tolerability of vaccine - Incidence and severity of signs and symptoms of reactogenicity such as diarrhea, and fever Incidence and severity of unsolicited adverse events</outcome>
      <timepoint>following vaccination through 180 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  healthy men or women,

          -  age 18 to 45 years inclusive;

          -  normal medical history and physical examination

          -  Women must have a negative pregnancy test.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  travel to a cholera endemic area in the previous 5 years;

          -  abnormal stool pattern or regular use of laxatives;

          -  Currently active unstable or undiagnosed medical conditions

          -  current or recent antibiotic use;

          -  pregnancy or nursing;

          -  Previously received a licensed or investigational cholera vaccine

          -  History of cholera or enterotoxigenic E. coli infection

          -  History of Guillain-Barré Syndrome

          -  Received or plans to receive any other licensed vaccines, except for seasonal
             influenza

          -  Recipient of bone marrow or solid organ transplant

          -  Malignancy (excluding non-melanotic skin cancers) or lymphoproliferative disorders
             diagnosed or treated during the past 5 years

          -  Use of systemic chemotherapy in the previous 5 years prior to the study

          -  any immunosuppressive medical condition</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>3146</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,SA,VIC,WA</recruitmentstate>
    <hospital>QIMR Berghofer Medical Research Institiue - Herston</hospital>
    <hospital>AUS Trials Pty Ltd - Sherwood</hospital>
    <hospital>CMAX - Adelaide</hospital>
    <hospital>Emeritis Research - Malvern East</hospital>
    <hospital>Nucleus Network - Melbourne</hospital>
    <hospital>Linear Clinical Research - Nedlands</hospital>
    <postcode>4006 - Herston</postcode>
    <postcode>4035 - Sherwood</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3145 - Malvern East</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>PaxVax, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary goal of this Phase III study is to compare 3 lots for consistency of manufacture.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02094586</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>